Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2025)

Historic Revenue for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $118.7 million.

  • Tarsus Pharmaceuticals' Revenue rose 14667.9% to $118.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.1 million, marking a year-over-year increase of 18243.88%. This contributed to the annual value of $183.0 million for FY2024, which is 94862.15% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Revenue stood at $118.7 million for Q3 2025, which was up 14667.9% from $102.7 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Revenue peaked at $118.7 million during Q3 2025, and registered a low of $338000.0 during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Revenue had a median value of $22.0 million in 2021 and averaged $34.3 million.
  • Examining YoY changes over the last 5 years, Tarsus Pharmaceuticals' Revenue showed a top increase of 285857.99% in 2022 and a maximum decrease of 9838.78% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Revenue (Quarter) stood at $338000.0 in 2021, then skyrocketed by 2858.58% to $10.0 million in 2022, then soared by 30.76% to $13.1 million in 2023, then skyrocketed by 407.86% to $66.4 million in 2024, then soared by 78.74% to $118.7 million in 2025.
  • Its last three reported values are $118.7 million in Q3 2025, $102.7 million for Q2 2025, and $78.3 million during Q1 2025.